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Metabolism of ticagrelor in patients 
with acute coronary syndromes
Piotr Adamski  1, Katarzyna Buszko2, Joanna Sikora3, Piotr Niezgoda1, Malwina Barańska1, 
Małgorzata Ostrowska1, Przemysław Paciorek1, Eliano P. Navarese1,4,5, Diana A. Gorog6 & 
Jacek Kubica1
Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary 
syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic 
activation to exert its antiplatelet action. Still, ticagrelor is extensively metabolized by hepatic 
CYP3A enzymes, and AR-C124910XX is its only active metabolite. A post hoc analysis of patient-level 
(n = 117) pharmacokinetic data pooled from two prospective studies was performed to identify clinical 
characteristics affecting the degree of AR-C124910XX formation during the first six hours after 180 mg 
ticagrelor loading dose in the setting of ACS. Both linear and multiple regression analyses indicated 
that ACS patients presenting with ST-elevation myocardial infarction or suffering from diabetes 
mellitus are more likely to have decreased rate of ticagrelor metabolism during the acute phase of ACS. 
Administration of morphine during ACS was found to negatively influence transformation of ticagrelor 
into AR-C124910XX when assessed with linear regression analysis, but not with multiple regression 
analysis. On the other hand, smoking appears to increase the degree of ticagrelor transformation in ACS 
patients. Mechanisms underlying our findings and their clinical significance warrant further research.
Excessive platelet activation and aggregation play essential role in the pathophysiology of acute coronary syn-
dromes (ACS), including acute myocardial infarction (AMI)1. Platelet inhibition with dual antiplatelet therapy, 
consisting of aspirin and one of P2Y12 receptor inhibitors, is the mainstay of ACS treatment. Blockade of platelet 
P2Y12 receptors is particularly important in ACS patients treated with percutaneous coronary interventions 
(PCI), as insufficient limitation of platelet activation increases the risk of thrombotic complications and death2.
Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with ACS. According to 
both European and American guidelines, it is the first line of treatment in a wide spectrum of ACS patients, 
including patients with ST-elevation myocardial infarction (STEMI) and moderate-to-high-risk non-ST-elevation 
ACS (NSTE-ACS), regardless of initial treatment strategy and including those pretreated with clopidogrel3–6.
Ticagrelor is a potent, reversibly binding, noncompetitive, oral P2Y12 receptor antagonist7. It is characterized 
by linear pharmacokinetics, and unlike other available P2Y12 receptor inhibitors administered orally, it does 
not necessitate metabolic activation to exert its antiplatelet action8. Still, ticagrelor is extensively metabolized by 
hepatic CYP3A enzymes. AR-C124910XX is the major of 10 identified ticagrelor metabolites and the only active 
one. Importantly, AR-C124910XX exerts at least as potent P2Y12 receptor inhibition as the parent drug9.
In healthy volunteers and patients with stable coronary artery disease ticagrelor is rapidly absorbed from the 
gastrointestinal tract and transformed into AR-C124910XX, with time to maximal concentration (tmax) 1.3–2 h 
and 1.5–3 h for the parent drug and its metabolite, respectively9–11. Numerous clinical factors have been shown 
not to influence bioavailability of ticagrelor or its antiplatelet effect in healthy volunteers12. However, in the setting 
of ACS where the expeditious onset of antiplatelet action is of vast importance, the intestinal uptake of ticagre-
lor may be significantly delayed, especially in patients administered with morphine and subjects suffering from 
STEMI, with ticagrelor tmax delayed up to 4–5 h13–16. Subsequently, lagged absorption postpones formation of 
AR-C124910XX and the onset of platelet inhibition exerted by ticagrelor and its active metabolite17.
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Two cytochrome P450 enzymes, CYP3A4 and CYP3A5, are responsible for the formation of AR-C124910XX18. 
Strong CYP3A inducers and inhibitors greatly affect pharmacokinetics of ticagrelor and its active metabolite, 
thus their co-administration with ticagrelor is contraindicated19,20. In healthy volunteers the bioavailability of 
AR-C124910XX ranges from 35% to 40% of ticagrelor plasma concentration, whereas in patients with AMI it 
may be as low as 21% during the initial hours of treatment8,9,21. Although ticagrelor may increase bioavailability of 
some statins, currently there are no data indicating that any of the medications routinely used for the treatment of 
ACS may affect metabolism of ticagrelor22. This also applies to morphine, the elementary analgesic used to relive 
chest pain in patients with ACS21. Therefore, it remains obscure what causes this discrepancy in the bioavailability 
of AR-C124910XX between healthy subjects and patients with ACS.
In the current study we sought to identify demographic and clinical factors affecting metabolism of ticagrelor 
into its active metabolite during the first six hours after ticagrelor loading dose (LD) in patients with ACS.
Methods
Study design. A post hoc analysis of integrated patient-level data pooled from two prospective, phase 
IV, single center, investigator-initiated trials evaluating pharmacokinetics of ticagrelor in patients with ACS 
(NCT02612116 - randomized, open-label, active-controlled study, n = 48; NCT02602444 - observational 
study, n = 73) was performed to determine whether ticagrelor metabolism in patients with ACS is affected by 
any of the recorded clinical characteristics. Both trials were conducted in accordance with the principles con-
tained in the Declaration of Helsinki and Good Clinical Practice guidelines. The studies were approved by The 
Ethics Committee of Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Poland 
(NCT02612116 - approval number KB 540/2015; NCT02602444 - approval number KB 617/2015). Written 
informed consent was obtained from each patient prior to any study specific procedures. Study protocols with 
full lists of inclusion and exclusion criteria, detailed description of methodology, and results of the two included 
trials were previously published in peer-reviewed journals14,23–25.
In line with the available literature8,9, the ratio of area under the plasma concentration-time curve for 
AR-C124910XX (AUCM) to AUC for ticagrelor (AUCT) was chosen as a marker of the degree of ticagrelor trans-
formation into its active metabolite ( )AUCAUCMT . A linear regression analysis of 16 available clinical features was 
planned to pinpoint characteristics related to lower AUC
AUC
M
T
 during the first six hours after a standard 180 mg ticagr-
elor LD in ACS patients. The analyzed variables included: age, gender, body mass index (BMI), obesity 
(BMI ≥ 30 kg/m2), creatinine plasma concentration at admission, glomerular filtration rate (GFR) at admission, 
type of ACS (STEMI vs. NSTE-ACS), type of administered ticagrelor tablets (integral vs. crushed), morphine 
co-administration, history of coronary artery disease, history of nonhemorrhagic stroke, left ventricle ejection 
fraction <50% at discharge, arterial hypertension, diabetes mellitus (DM), dyslipidemia, and current smoking 
(Table 1). A subsequent multiple regression analysis was intended to verify which characteristics are connected 
with lower AUC
AUC
M
T
 during the initial period of ACS treatment with ticagrelor.
n = 117
Age in years 63.5 ± 9.9
Female 40 (34)
BMI in kg/m2 27.8 ± 4.4
Obesity (BMI ≥ 30 kg/m2) 30 (26)
Creatinine at admission in mg/dL 0.87 ± 0.19
GFR at admission in mL/minute 83.3 ± 16.0
STEMI 46 (39)
NSTE-ACS 71 (61)
NSTEMI 24 (21)
UA 47 (40)
Integral ticagrelor tablets 86 (74)
Morphine administration 33 (28)
History of CAD 35 (30)
Nonhemorrhagic stroke 9 (8)
LVEF at discharge <50% 59 (50)
Hypertension 75 (64)
Diabetes mellitus 25 (21)
Dyslipidemia 104 (89)
Current smoker 43 (37)
Table 1. Baseline characteristics of the study participants. Data are shown as mean ± standard deviation or 
number (%). BMI: body mass index, CAD: coronary artery disease, GFR: glomerular filtration rate, LVEF: left 
ventricle ejection fraction, NSTE-ACS: non-ST-elevation acute coronary syndrome, NSTEMI: non-ST-elevation 
myocardial infarction, STEMI: ST-elevation myocardial infarction, UA: unstable angina.
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Patient population. The diagnosis of STEMI, non-ST-elevation myocardial infarction (NSTEMI) or unsta-
ble angina (UA), and provision of informed consent for coronary angiography and PCI were required for the cur-
rent analysis entry. The diagnosis of STEMI and NSTEMI was made according to the Third Universal Definition 
of Myocardial Infarction26. UA was diagnosed according to the 2015 European Society of Cardiology guidelines 
for the management of NSTE-ACS4. To avoid any potential cofactors affecting hepatic metabolism of ticagrelor, 
patients on therapy with any strong CYP3A inhibitors or inducers were not included in either of the studies. All 
subjects were P2Y12 receptor inhibitor-naive at the time of enrolment for each study, and received 180 mg LD of 
ticagrelor as a part of dual antiplatelet therapy with aspirin. Overall 121 ACS patients were screened, and 117 were 
eventually included in the analysis (Fig. 1). Patients with no detectable ticagrelor in plasma within the observation 
period were not included in the analysis.
Concomitant treatment. During their participation in the trials, all patients were treated according to the 
European Society of Cardiology (ESC) guidelines4,27. Standard therapy included aspirin, beta-blockers, statins, 
and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, if not contraindicated. During 
the periprocedural period, all study participants received unfractionated heparin in body weight adjusted dose 
according to the ESC recommendations. To ensure that no potential drug-drug interactions affect the results of 
this analysis, each patient’s individual data were screened to identify any treatment with medications known to 
interplay with metabolism of ticagrelor. However, after a careful inspection none of the patients from both trials 
was excluded from the analysis due to this reason.
Pharmacokinetic evaluation. Blood samples for the pharmacokinetic assessment were obtained at pre-
specified time points before and after 180 mg ticagrelor LD, using an 18-gauge venous catheter inserted into a 
forearm vein (at baseline, 30 minutes, 1, 2, 3, 4 and 6 hours after ticagrelor LD in both studies, and additionally at 
15 and 45 minutes after ticagrelor LD in patients included in NCT02612116 study) (Fig. 2)23,24. The samples were 
collected into lithium-heparin vacuum test tubes and immediately after collection each sample was placed on dry 
ice and transferred to the central laboratory. Subsequently, within 20 min from collection, blood specimens were 
centrifuged at 1500 g for 12 min at 4 °C. Within 10 min postcentrifugation, obtained plasma samples were stored 
at temperature below −60 °C until analyzed. Ticagrelor and AR-C124910XX plasma concentrations were ana-
lyzed with liquid chromatography coupled with tandem mass spectrometry, using a validated method13,28. Lower 
limits of quantification were 4.69 ng/mL for both ticagrelor and AR-C124910XX.
Statistical analysis. Statistical calculations were performed using the Statistica 12.5 package (StatSoft, Tulsa, 
OK, USA). Pharmacokinetic calculations and plots were made using the Matlab R2014 software (Mathworks, 
Natick, MA, USA). Trapezoidal rule was applied to calculate AUC. Data for AUC
AUC
M
T
, age, BMI, creatinine plasma con-
centration and GFR were presented as means with standard deviations. AUC
AUC
M
T
 was evaluated for the period from 0 to 
6 hours. Continuous variables were compared between both study arms with the Student’s t-test and Mann–Whitney 
Figure 1. Patient flow diagram.
Figure 2. Blood sampling schedules.
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U test, depending on the presence or absence of the normal distribution. To determine variables associated with 
changed AUC
AUC
M
T
 values, we performed a linear regression analysis for each feature listed in Table 1. A subsequent mul-
tiple regression analysis included characteristics that were found to significantly alter AUC
AUC
M
T
. Finally, a supplementary 
multiple regression analysis was performed to assess the impact on AUC
AUC
M
T
 exerted by clinical variables used for the 
main multiple regression analysis in addition with variables that were suggested by the literature to affect metabolism 
of ticagrelor. In all cases, two-sided p-values < 0.05 were considered significant.
Data availability. The dataset from NCT02602444 trial analyzed during the current study is available in 
the figshare.com repository (doi:10.6084/m9.figshare.5396989). The dataset from NCT02612116 trial analyzed 
during the current study are available from the corresponding author on reasonable request.
Results
Mean AUC
AUC
M
T
for the whole analyzed population was 20.4 ± 10.4%. A linear regression analysis of clinical variables 
listed in Table 1 revealed that diagnosis of STEMI, presence of DM and co-administration of morphine are inde-
pendent predictors of lower AUC
AUC
M
T
 during the first six hours after ticagrelor LD in ACS patients (AUC
AUC
M
T
 in STEMI: 
−3.7%, 95% confidence interval [CI] −5.5% to −1.8%, p = 0.0001; AUC
AUC
M
T
 in DM: −2.3%, 95% CI −4.6% to 
−0.03%, p = 0.048; AUC
AUC
M
T
 in patients co-administered with morphine: −3.0%, 95% CI −5.0% to −1.0%, p = 0.004) 
(Table 2).
Furthermore, a multiple regression analysis confirmed that both diagnosis of STEMI (−6.8%, 95% CI −10.9% 
to −2.8%, p < 0.001) and DM (−5.5%, 95% CI −9.8% to −1.2%, p = 0.013), but not use of morphine (p = 0.22), 
are connected with lower AUC
AUC
M
T
 (Table 3). An additional, exploratory multiple regression analysis of variables 
included in the main multiple regression analysis together with age, gender, GFR and smoking status has been 
performed due to available data from another studies suggesting that these characteristics may also affect the 
degree of ticagrelor metabolism into AR-C124910XX29–31. This supplementary analysis again showed that pres-
ence of STEMI (−8.2%, 95% CI −12.4% to −4.0%, p = 0.0002) and DM (−5.9%, 95% CI −10.3% to −1.6%, 
p = 0.008) were related to lower AUC
AUC
M
T
. Moreover, it also revealed that smoking patients had greater degree of 
Regression 
coefficient
95% confidence 
interval p value R2
Age (per year) 0.02 −0.17; 0.21 0.84 0.02
Female 0.04 −1.97; 2.05 0.97 <0.001
BMI (per kg/m2) −0.37 −0.81; 0.06 0.09 0.16
Obesity (BMI ≥ 30 kg/m2) −1.33 −3.49; 0.83 0.22 0.01
Creatinine at admission (per mg/dL) −3.83 −14.08; 6.42 0.46 0.07
GFR at admission (per mL/minute) 0.05 −0.07; 0.17 0.42 0.07
STEMI −3.67 −5.51; −1.83 0.0001 0.12
Integral ticagrelor tablets (vs. crushed 
ticagrelor tablets) −2.05 −4.19; 0.09 0.06 0.03
Morphine administration −3.04 −5.04; −0.98 0.004 0.07
History of CAD 0.39 −1.70; 2.49 0.71 0.001
Nonhemorrhagic stroke 0.10 −3.50; 3.69 0.96 <0.001
LVEF at discharge < 50% −1.22 −3.12; 0.68 0.21 0.01
Hypertension 0.55 −1.43; 2.54 0.58 <0.01
Diabetes mellitus −2.32 −4.62; −0.03 0.048 0.03
Dyslipidemia −0.17 −3.22; 2.88 0.91 <0.001
Current smoker 0.63 −1.36; 2.62 0.53 <0.01
Table 2. The impact of clinical features on the rate of ticagrelor metabolism according to linear regression 
analyses for each variable. BMI: body mass index, CAD: coronary artery disease, GFR: glomerular filtration 
rate, LVEF: left ventricle ejection fraction, STEMI: ST-elevation myocardial infarction.
Regression 
coefficient
Standard 
error
95% confidence 
interval p value
R2 (overall 
significance)
Constant 25.0 1.3 22.5; 27.6 0.0001
0.18 (0.000045)
STEMI −6.8 2.0 −10.9; −2.8 0.0009
Morphine co-administration −2.7 2.8 −7.0; 1.7 0.22
Diabetes mellitus −5.5 2.2 −9.8; −1.2 0.013
Table 3. The impact of clinical features on the rate of ticagrelor metabolism according to the main multiple 
regression analysis. STEMI: ST-elevation myocardial infarction.
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transformation of ticagrelor into its active metabolite (4.2%, 95% CI 0.2% to 8.3%, p = 0.04), while lack of rela-
tionship was found for age, gender, morphine administration and GFR (Table 4). The R2 value of 0.18 for the 
primary and of 0.22 for supplementary multiple regression analysis indicated that 18% and 22% of the variability 
in AUC
AUC
M
T
 can be explained by each model, respectively.
In a direct comparison we found that patients with STEMI, DM or those treated with morphine had signifi-
cantly lower AUC
AUC
M
T
 compared with patients with NSTE-ACS, non-diabetic or morphine-naive patients, respec-
tively (STEMI vs. NSTE-ACS: 16.0% ± 11.6% vs. 23.3% ± 8.5%, p = 0.0001; morphine vs. morphine-naive: 
16.1% ± 12.5% vs. 22.1% ± 9.0%, p = 0.004; DM vs. non-DM: 16.8% ± 9.7% vs. 21.4% ± 10.4%, p = 0.048). When 
we compared AUC
AUC
M
T
 for smokers and non-smokers the difference between the groups was not significant 
(21.2% ± 9.6% vs. 20.0% ± 10.9%; p = 0.53) (Fig. 3).
Discussion
Our analysis of patient-level pharmacokinetic data from two prospective trials revealed that ACS patients pre-
senting with STEMI or suffering from DM are more likely to have decreased ticagrelor metabolism rate during 
the acute phase of ACS. Analgesic treatment with morphine in this setting was found to negatively influence 
transformation of ticagrelor into AR-C124910XX when assessed with linear regression analysis, but this effect 
was not significant anymore when evaluated with multiple regression analyses. On the other hand, smoking 
Parameter
Regression 
coefficient
Standard 
error
95% confidence 
interval p value
R2 (overall 
significance)
Constant 17.1 7.2 2.8; 31.4 0.02
0.21 (0.00014)
Age 0.1 0.1 −0.1; 0.3 0.36
Gender 1.6 2.0 −2.3; 5.4 0.43
STEMI −8.2 2.1 −12.4; −4.0 0.0002
Morphine co-administration −2.2 2.2 −6.6; 2.1 0.31
Current smoker 4.2 2.0 0.2; 8.3 0.04
Diabetes mellitus −5.9 2.2 −10.3; −1.6 0.008
Table 4. The impact of clinical features on the rate of ticagrelor metabolism according to the additional 
multiple regression analysis. STEMI: ST-elevation myocardial infarction.
Figure 3. AR-C124910XX to ticagrelor plasma concentration ratios. Comparison of metabolite to parent drug 
concentration ratios based on the presence of STEMI (vs. NSTE-ACS) (A), morphine administration (B), DM 
(C) or smoking status (D). AUCM/AUCT: the ratio of area under the plasma concentration-time curve for AR-
C124910XX to area under the plasma concentration-time curve for ticagrelor; DM: diabetes mellitus; NSTE-
ACS: non-ST-elevation acute coronary syndrome; STEMI: ST-elevation myocardial infarction.
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appears to increase the degree of ticagrelor transformation expressed as AUC
AUC
M
T
 in ACS patients. Our study shows 
that increased bioavailability of crushed ticagrelor tablets does not influence the rate of AR-C124910XX forma-
tion following ticagrelor LD in ACS patients25,32,33. Admittedly, all STEMI patients included in our study received 
integral ticagrelor tablets, therefore results of our linear regression analysis in regard to ticagrelor pill formulation 
may not be applicable to this ACS subtype and require further investigation.
Excessive activation of thrombocytes is one of the main underlying pathomechanisms of ACS. High platelet 
reactivity (HPR) is a risk factor for adverse thrombotic events in ACS patients, including stent thrombosis, a 
potentially fatal complication of PCI2. Moreover, HPR can also be associated with increased mortality in ACS 
patients34. Thus, obtaining a quick and powerful platelet blockade is necessary from the very early stage of ACS 
treatment, even in conservatively managed patients. Ticagrelor, the first line P2Y12 receptor inhibitor in ACS, 
thanks to its favorable pharmacokinetics provides a strong antiplatelet action swiftly after oral ingestion. It has to 
be noted though, that ticagrelor absorption and onset of action are delayed in patients with ACS compared with 
healthy volunteers or patients with stable coronary artery disease.
Although ticagrelor is responsible for the majority of the observed antiplatelet effect, its active metabolite is 
equipotent in P2Y12 receptor inhibition and also plays an important role in limiting excessive platelet activa-
tion9. Ticagrelor is metabolized and transformed into AR-C124910XX predominantly by CYP3A4 and CYP3A5 
enzymes18. Therefore, metabolism of ticagrelor is affected by concomitant administration of strong CYP3A induc-
ers or inhibitors. CYP3A inducers may essentially decrease total exposure to ticagrelor and its active metabolite 
even by 86% and 46%, respectively, as seen in subjects receiving rifampicin19. On the other hand, strong CYP3A4 
inhibitors, for example ketoconazole, may increase ticagrelor exposure by 632%, simultaneously decreasing bio-
availability of AR-C124910XX by 56%20. Due to the described drug-drug interactions, use of ticagrelor together 
with powerful CYP3A4 inducers and inhibitors is contraindicated. On the other hand, although certain genetic 
variants have been shown to modestly affect ticagrelor and AR-C124910XX pharmacokinetics in the setting of 
ACS, they were not associated with any detectable effect on efficacy or safety during ticagrelor treatment35.
The impact of different clinical characteristics on ticagrelor pharmacokinetics has been evaluated in several 
previous trials. A study by Teng et al. showed that in healthy volunteers the overall exposure to AR-C124910XX 
after a single 200 mg loading dose of ticagrelor was 37% higher in women than in men, and 48% higher in elderly 
than in young individuals, however these differences were proportional to ticagrelor bioavailability between the 
groups29. In a different trial, patients with severe renal impairment (GFR < 30 mL/min) compared with volun-
teers with normal renal function (GFR > 80 mL/min) had 20% lower ticagrelor and 17% higher AR-C124910XX 
bioavailability following a single 180 mg LD of ticagrelor. Subsequently, patients with impaired renal function 
had 48% higher metabolite to parent ratio for AUC30. Butler and Teng also demonstrated that patients with 
severe hepatic impairment (Child-Pugh class A) had 23% and 66% higher total bioavailability of ticagrelor and its 
metabolite, respectively, than volunteers with normal liver function after single 90 mg ticagrelor dose36. Moreover, 
population pharmacokinetic model developed for ticagrelor indicated that smoking decreases apparent ticagre-
lor clearance, simultaneously increasing apparent clearance of AR-C124910XX31. Despite the pharmacokinetic 
differences observed in the aforementioned studies a substantial platelet inhibition was obtained regardless of 
gender, age, presence of severe renal or mild hepatic impairment, or smoking status, and no adjustment in tica-
grelor dose was considered necessary in the described populations11,29,30,36. Nevertheless, it has to be underlined 
that these observations were made based on the results obtained from individuals without ACS. Recent pharma-
cokinetic and pharmacodynamic studies clearly show that presence of ACS, and especially STEMI, delays and 
decreases bioavailability, onset of action and antiplatelet effect of ticagrelor13–16,37. It is established that presence 
of HPR, which may be caused by impaired ticagrelor pharmacokinetics, is related to adverse thrombotic events 
in patients with ACS2,34.
In subanalysis of the IMPRESSION study we have reported that although morphine administration did not 
affect AUC
AUC
M
T
 in patients with AMI, the observed AUC
AUC
M
T
 values were lower than these reported for healthy volunteers 
(21–25% vs. 35–40%)8,9,21. Similarly, in the current analysis the mean AUC
AUC
M
T
 was approximately 20% for the whole 
study population. It could be speculated that it is due to delayed absorption of ticagrelor in ACS combined with 
relatively short window of observation (the first six hours after ticagrelor LD) compared with trials in healthy 
volunteers.
In line with previous studies, the results of the current analysis show that presence of STEMI essentially dis-
turbs pharmacokinetic profile of ticagrelor13,14,16. From all examined clinical features STEMI had the greatest 
negative impact on AUC
AUC
M
T
 (beta-coefficient for supplementary multiple regression analysis = −0.38). Our results 
show that the mechanism of impaired ticagrelor pharmacokinetics seen in patients with STEMI during the initial 
hours after the LD may be multifactorial and related not only to slower intestinal absorption, but also to dimin-
ished hepatic metabolism. Interestingly, presence of DM was also found to have significant negative influence on 
AUC
AUC
M
T
 in all performed analyses (beta-coefficient for supplementary multiple regression analysis = −0.24). DM is 
one of the most important and most common risk factors for ACS. It has to be considered that the effect of DM 
on AUC
AUC
M
T
 can further aggravate the effect of STEMI, and that the co-existence of these two conditions is not rare. 
Admittedly, the mechanisms behind the effect of STEMI or DM on AUC
AUC
M
T
 remain unknown.
The impact of the remaining evaluated features on ticagrelor hepatic transformation during the first six hours 
after ticagrelor LD is ambiguous. Morphine, which delays and attenuates bioavailability of ticagrelor in patients 
with AMI13, in our analysis significantly decreased AUC
AUC
M
T
 only when assessed with linear regression analysis. 
Morphine follows metabolic pathway which does not include CYP3A enzymes, thus clinically relevant interaction 
with ticagrelor metabolism is rather unlikely38. Our supplementary multiple regression analysis model included 
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smoking as a potential factor influencing ticagrelor metabolism, based on a pharmacokinetic model for ticagrelor 
and its metabolite suggesting that smoking alters apparent clearance of ticagrelor and AR-C124910XX31. In our 
analysis habitual smoking was the only clinical characteristic that positively affects AUC
AUC
M
T
 (beta-coefficient for 
supplementary multiple regression analysis = 0.20). The mechanism behind this finding also remains undeter-
mined as smoking does not affect CYP3A-mediated metabolism31.
In subgroup analyses of the PLATO study the cardiovascular benefit was consistent in patients treated 
with ticagrelor compared with those treated with clopidogrel irrespective of type of treatment for STEMI or 
NSTE-ACS, diabetic status and glycemic control, or smoking status39–42. Thus, the clinical significance of our 
findings is obscure, uncertain and warrants further research.
Study limitations. One could perceive lack of pharmacodynamic data as a limitation of this analysis, how-
ever it was the authors’ intention to focus on ticagrelor metabolism only. It also has to be noted that the ethnicity 
of the examined group was homogenous (100% Caucasian), which closely reflects the ethnical structure seen in 
Poland, where both analyzed studies were conducted. Additionally, smoking status was collected only based on 
information obtained from each patient, and was not validated objectively.
Moreover, several limitations resulted from the design of the included trials. Neither of two studies evaluated 
clinical endpoints, thus these data were not available. The information on the time span between the onset of chest 
pain and ticagrelor loading dose was incomplete, and therefore was not included in the analysis. The liver func-
tion was not evaluated at the time of enrolment for the analyzed studies, and the exclusion due to liver function 
impairment was made based on medical history of severe hepatic disease only.
Conclusions
The degree of ticagrelor hepatic transformation into its active metabolite following a standard 180 mg LD in the 
setting of ACS is decreased in patients with STEMI and DM. Morphine may be related to smaller, and smoking 
with greater rate of ticagrelor metabolism in patients with ACS, but these data are not completely conclusive.
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